Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

B.H. Park, T. Hwang, T.C. Liu, D.Y. Sze, J.S. Kim, H.C. Kwon, S.Y. Oh, S.Y. Han, J. Yoon, S. Hong, A. Moon, K. Speth, C. Park, Y.J. Ahn, M. Daneshmand, B.G. Rhee, H.M. Pinedo, J. Bell, D.H. Kirn

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)533-542
JournalLancet Oncology
Volume9
Issue number6
DOIs
Publication statusPublished - 2008

Cite this

Park, B.H. ; Hwang, T. ; Liu, T.C. ; Sze, D.Y. ; Kim, J.S. ; Kwon, H.C. ; Oh, S.Y. ; Han, S.Y. ; Yoon, J. ; Hong, S. ; Moon, A. ; Speth, K. ; Park, C. ; Ahn, Y.J. ; Daneshmand, M. ; Rhee, B.G. ; Pinedo, H.M. ; Bell, J. ; Kirn, D.H. / Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. In: Lancet Oncology. 2008 ; Vol. 9, No. 6. pp. 533-542.
@article{9a217c18b0d0424182fb4e40f95b3e71,
title = "Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial",
author = "B.H. Park and T. Hwang and T.C. Liu and D.Y. Sze and J.S. Kim and H.C. Kwon and S.Y. Oh and S.Y. Han and J. Yoon and S. Hong and A. Moon and K. Speth and C. Park and Y.J. Ahn and M. Daneshmand and B.G. Rhee and H.M. Pinedo and J. Bell and D.H. Kirn",
year = "2008",
doi = "10.1016/S1470-2045(08)70107-4",
language = "English",
volume = "9",
pages = "533--542",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC, Oh, SY, Han, SY, Yoon, J, Hong, S, Moon, A, Speth, K, Park, C, Ahn, YJ, Daneshmand, M, Rhee, BG, Pinedo, HM, Bell, J & Kirn, DH 2008, 'Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial' Lancet Oncology, vol. 9, no. 6, pp. 533-542. https://doi.org/10.1016/S1470-2045(08)70107-4

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. / Park, B.H.; Hwang, T.; Liu, T.C.; Sze, D.Y.; Kim, J.S.; Kwon, H.C.; Oh, S.Y.; Han, S.Y.; Yoon, J.; Hong, S.; Moon, A.; Speth, K.; Park, C.; Ahn, Y.J.; Daneshmand, M.; Rhee, B.G.; Pinedo, H.M.; Bell, J.; Kirn, D.H.

In: Lancet Oncology, Vol. 9, No. 6, 2008, p. 533-542.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

AU - Park, B.H.

AU - Hwang, T.

AU - Liu, T.C.

AU - Sze, D.Y.

AU - Kim, J.S.

AU - Kwon, H.C.

AU - Oh, S.Y.

AU - Han, S.Y.

AU - Yoon, J.

AU - Hong, S.

AU - Moon, A.

AU - Speth, K.

AU - Park, C.

AU - Ahn, Y.J.

AU - Daneshmand, M.

AU - Rhee, B.G.

AU - Pinedo, H.M.

AU - Bell, J.

AU - Kirn, D.H.

PY - 2008

Y1 - 2008

U2 - 10.1016/S1470-2045(08)70107-4

DO - 10.1016/S1470-2045(08)70107-4

M3 - Article

VL - 9

SP - 533

EP - 542

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 6

ER -